Split-Bolus Injection Producing Simultaneous Late Arterial and Portal Venous Phases in CT Enterography: Preliminary Results.

OBJECTIVE: The purpose of this article is to evaluate the image quality and added value of split-bolus contrast agent injection combining late arterial and portal venous phases compared with single-bolus contrast agent injection late arterial phase CT enterography. MATERIALS AND METHODS: Consecutive patients who underwent CT enterography before and after implementation of a single-bolus CT enterography protocol were included. Attenuation and contrast-to-noise ratio (CNR) were assessed by ROI measurements of the bowel wall and arterial and venous structures. Subjective enhancement of the bowel wall (1, arterial; 2, mucosal; 3, transmural; 4, transmural with mucosal hyperenhancement) and bowel abnormalities were assessed by two independent readers. MR enterography examinations, endoscopy reports, and surgery reports within 30 days after CT enterography were used to produce a composite outcome. RESULTS: Sixty-six patients were included in our study: 33 (mean [± SD] age, 46.0 ± 19.8 years) who underwent split-bolus CT enterography and 33 (mean age, 49.9 ± 19.0 years) who underwent single-bolus CT enterography. Bowel wall attenuation and CNR were higher for split-bolus CT enterography than for single-bolus CT enterography at 120 kVp (enhancement, 98.7 ± 23.1 HU vs 85.1 ± 23.3 HU; CNR, 6.4 ± 2.5 vs 4.4 ± 2.3; p < 0.01). Subjective ratings of bowel wall enhancement were higher with the split-bolus CT enterography than the single-bolus CT enterography (2.6 ± 0.8 vs 2.3 ± 0.6; p < 0.001). Split-bolus CT enterography led to a higher detection rate of mucosal hyperenhancement than did single-bolus CT enterography in patients with active inflammatory bowel disease (100.0% [7/7; 95% CI, 59.0-100.0%] vs 33.3% [2/6; 95% CI, 4.3-77.7%]; p = 0.02), whereas both protocols had a specificity of 100.0% (9/9). CONCLUSION: Split-bolus CT enterography led to improved CNR (47%) compared with single-bolus CT enterography and significantly increased the detection rate of mucosal hyperenhancement in patients with active inflammatory bowel disease.

Limited added utility of performing follow-up contrast-enhanced CT in patients undergoing initial non-enhanced CT for evaluation of flank pain in the emergency department.

In our emergency department (ED), patients with flank pain often undergo non-enhanced computed tomography (NECT) to assess for nephroureteral (NU) stone. After immediate image review, decision is made regarding need for subsequent contrast-enhanced CT (CECT) to help assess for other causes of pain. This study aimed to review the experience of a single institution with this protocol and to assess the utility of CECT. Over a 6 month period, we performed a retrospective analysis on ED patients presenting with flank pain undergoing CT for a clinical diagnosis of nephroureterolithiasis. Patients initially underwent abdominopelvic NECT. The interpreting radiologist immediately decided whether to obtain a CECT to evaluate for another etiology of pain. Medical records, CT reports and images, and 7-day ED return were reviewed. CT diagnoses on NECT and CECT were compared. Additional information from CECT and changes in management as documented in the patient's medical record were noted. Three hundred twenty-two patients underwent NECT for obstructing NU stones during the study period. Renal or ureteral calculi were detected in 143/322 (44.4 %). One hundred fifty-four patients (47.8 %) underwent CECT. CECT added information in 17/322 cases (5.3 %) but only changed management in 6/322 patients (1.9 %). In four of these patients with final diagnosis of renal infarct, splenic infarct, pyelonephritis and early acute appendicitis in a thin patient, there was no abnormality on the NECT (4/322 patients, 1.2 %). In the remaining 2 patients, an abnormality was visible on the NECT. In patients presenting with flank pain with a clinical suspicion of nephroureterolithiasis, CECT may not be indicated. While CECT provided better delineation of an abnormality in 5.3 % of cases, changes in management after CECT occurred only in 2 %. This included 1 % of patients in whom a diagnosis of organ infarct, pyelonephritis or acute appendicitis in a thin patient could only be made on CECT.

Split-bolus spectral multidetector CT of the pancreas: assessment of radiation dose and tumor conspicuity.

PURPOSE: To assess tumor conspicuity and radiation dose with a new multidetector computed tomography (CT) protocol for pancreatic imaging that combines spectral CT and split-bolus injection. MATERIALS AND METHODS: This study was approved by the institutional review board and compliant with HIPAA. The requirement for informed consent was waived. One hundred sixty-three consecutive patients referred for possible pancreatic mass underwent CT with either a standard or split-bolus spectral CT protocol depending on scanner availability. Split-bolus spectral CT (CT unit with spectral imaging) combines pancreatic and portal venous phases in a single scan: 70 seconds before CT, 100 mL of contrast material is injected for the portal venous phase followed approximately 35 seconds later by injection of 40 mL of contrast material to boost the pancreatic phase. Bolus tracking after the second bolus initiates scanning 15 seconds after aorta enhancement reaches 280 HU. Images were reconstructed at 60 and 77 keV. The standard protocol (64-detector row unit) included unenhanced and pancreatic and portal venous phase imaging, with a single contrast material injection timed with bolus tracking 15 seconds after aortic enhancement of 300 HU for the pancreatic phase and 32 seconds later for the portal venous phase. Tumor conspicuity (difference in attenuation between tumor and pancreatic parenchyma) and contrast-to-noise ratio (CNR) were determined. Attenuation of aorta, main portal vein, and liver were measured. Patient size and per-examination radiation dose were recorded. The heteroscedastic t test, Fisher exact test, and Mann-Whitney test were used for statistical analysis. RESULTS: There were no significant differences in age, weight, and body mass index between patients in the standard CT (46 of 80 patients had lesions) and split-bolus spectral CT (39 of 83 patients had lesions) groups; however, there were significantly more women in the split-bolus group (P = .02). Tumor conspicuity and CNR were higher with the 60-keV split-bolus protocol (89.1 HU ± 56.6 and 8.8 ± 6.2, respectively) than with the pancreatic or portal venous phase of the standard protocol (43.5 HU ± 28.4 and 4.5 ± 3.0, and 51.5 HU ± 30.3 and 5.6 ± 4.0, respectively; P < .01 for all comparisons). Dose-length product was 1112 mGy · cm ± 437 with the standard protocol and 633 mGy · cm ± 105 with the split-bolus protocol (P < .001). CONCLUSION: Split-bolus spectral multidetector CT resulted in vascular, liver, and pancreatic attenuation and tumor conspicuity equal to or greater than that with multiphase CT, with a 43% reduction in radiation dose.

Spectral CT with metal artifacts reduction software for improvement of tumor visibility in the vicinity of gold fiducial markers.

PURPOSE: To evaluate spectral computed tomography (CT) with metal artifacts reduction software (MARS) for reduction of metal artifacts associated with gold fiducial seeds. MATERIALS AND METHODS: Thirteen consecutive patients with 37 fiducial seeds implanted for radiation therapy of abdominal lesions were included in this HIPAA-compliant, institutional review board-approved prospective study. Six patients were women (46%) and seven were men (54%). The mean age was 61.1 years (median, 58 years; range, 29-78 years). Spectral imaging was used for arterial phase CT. Images were reconstructed with and without MARS in axial, coronal, and sagittal planes. Two radiologists independently reviewed reconstructions and selected the best image, graded the visibility of the tumor, and assessed the amount of artifacts in all planes. A linear-weighted κ statistic and Wilcoxon signed-rank test were used to assess interobserver variability. Histogram analysis with the Kolmogorov-Smirnov test was used for objective evaluation of artifacts reduction. RESULTS: Fiducial seeds were placed in pancreas (n = 5), liver (n = 7), periportal lymph nodes (n = 1), and gallbladder bed (n = 1). MARS-reconstructed images received a better grade than those with standard reconstruction in 60% and 65% of patients by the first and second radiologist, respectively. Tumor visibility was graded higher with standard versus MARS reconstruction (grade, 3.7 ± 1.0 vs 2.8 ± 1.1; P = .001). Reduction of blooming was noted on MARS-reconstructed images (P = .01). Amount of artifacts, for both any and near field, was significantly smaller on sagittal and coronal MARS-reconstructed images than on standard reconstructions (P < .001 for all comparisons). Far-field artifacts were more prominent on axial MARS-reconstructed images than on standard reconstructions (P < .01). Linear-weighted κ statistic showed moderate to perfect agreement between radiologists. CT number distribution was narrower with MARS than with standard reconstruction in 35 of 37 patients (P < .001). CONCLUSION: Spectral CT with use of MARS improved tumor visibility in the vicinity of gold fiducial seeds.

Female breast, lung, and pelvic organ radiation from dose-reduced 64-MDCT thoracic examination protocols: a phantom study.

OBJECTIVE: We compared phantom organ doses delivered to breast, lung, and pelvis by five protocols using current dose reduction methods for routine chest CT and pulmonary CT angiography. MATERIALS AND METHODS: We measured the radiation dose to an anthropomorphic phantom using 64-MDCT with metal oxide semiconductor field effect transistor (MOSFET) detectors in the breast (skin and parenchyma), the lungs, and the pelvis (upper and lower). We compared the following five protocols: protocol 1, 120 kVp, automatic dose modulation, 120-320 mA; protocol 2, 120 kVp, automatic dose modulation, 60-200 mA; protocol 3, 100 kVp and fixed dose of 200 mA; protocol 4, 120 kVp, automatic dose modulation, 200-394 mA; and protocol 5, 80 kVp and fixed dose of 120 mA. Organ doses in milligrays and as a percentage of the volume CT dose index (CTDI(vol)) were compared using the analysis of variance for repeated measurements. RESULTS: Protocol 1 delivered the highest breast dose (mean ± SD, 15.8 ± 1.8 mGy; 110.5% of CTDI(vol)). A decrease in breast radiation of more than 50% was achieved with protocol 3 (4.8 ± 1.8 mGy; 91.7% of CTDI(vol)) compared with protocol 4 (13.1 ± 5.5 mGy; 87.0% of CTDI(vol)) (p = 0.003). The lung received the highest organ dose regardless of the protocol (protocol 4: 21.5 ± 1.7 mGy; 142.5% of CTDI(vol)). Pelvic radiation was low regardless of protocol and did not exceed 0.2 mGy (up to 3.7% of CTDI(vol); p = 0.118-0.999). CONCLUSION: The results of this anthropomorphic phantom study showed substantial and significant variation in radiation doses to the breast and lungs depending on the scanning protocol used with the potential for over threefold dose reduction.

Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT.

OBJECTIVE: The purpose of this article is to evaluate the incidence of contrast-induced nephropathy (CIN) and the effects of associated risk factors in patients with multiple myeloma undergoing contrast-enhanced CT (CECT) with IV administration of nonionic iodinated contrast agent. MATERIALS AND METHODS: This retrospective review of medical records identified patients with a diagnosis of myeloma who underwent a CECT examination of the chest, abdomen, or pelvis between January 1, 2005, and December 1, 2008. Analysis for CIN, as defined by an increase in creatinine level after the CECT examination of 25% or more, or of 0.5 mg/dL, compared with the level before the CECT examination, both within 48 hours and within 7 days, was performed. Statistical correlations between the development of CIN and creatinine level before CECT examination, patient location, type and amount of contrast agent, blood urea nitrogen-creatinine ratio, history of diabetes, hypercalcemia, Bence Jones proteinuria, ß(2)-microglobulin level, albumin level, International Myeloma Staging System stage, and history of myeloma provided at the time the CT examination was ordered were calculated. RESULTS: Forty-six patients who completed 80 unique examinations were included; their average creatinine level before CECT examination was 0.97 mg/dL. There was no significant difference in the average creatinine levels before CT examination between patients without and those with CIN. Four (5%) and 12 (15%) patients developed CIN within 48 hours and 7 days, respectively. Only serum ß(2)-microglobulin level showed a statistically significant (p = 0.03) correlation with the development of CIN. CONCLUSION: The incidence of CIN in patients with multiple myeloma with a normal creatinine level is low and correlates with ß(2)-microglobulin levels. The administration of contrast agent in this patient population is safe but should be based on the potential benefit of the examination and the expected low risk of developing CIN.

Combined vascular-excretory phase MDCT angiography in the preoperative evaluation of renal donors.

OBJECTIVE: The objective of our study was to test a dose reduction protocol that uses combined vascular-excretory phase scanning achieved by split IV contrast injection and compare it with conventional multiphase MDCT angiography (MDCTA) in evaluating potential renal donors. MATERIALS AND METHODS: This study is a review of MDCTA examinations of 54 potential renal donors scanned on 16- and 64-MDCT. The IV bolus was split: 50 mL was administered 3 minutes before scanning and a second injection of 70-100 mL was administered at a rate of 4-6 mL/s, with CT angiography started by bolus tracking. The second vascular (venous) phase was acquired 20 seconds later. Two readers reviewed the two phases, assessed vascular and parenchymal anatomy and variants or abnormalities, graded the added value of the venous phase on a 5-point scale, and took attenuation measurements in Hounsfield units. The operative notes of 39 subjects were reviewed as the reference standard for anatomic findings and compared with CT reports. RESULTS: All of the relevant anatomy findings, according to the operative notes, were accurately depicted by MDCTA, and all were well recognized on the arterial phase. The arterial phase combined information from the arterial, venous, parenchymal, and excretory phases. The venous phase was inferior to the arterial phase in assessing the renal arteries without additional venous, parenchymal, or excretory phase information. The mean renal artery attenuation was 355 HU in the first phase versus 173 HU in the second phase (p<0.0001). The mean renal vein attenuation was not significantly different between the two phases. The parenchymal system and excretory system were equally well depicted in both vascular phases. CONCLUSION: Split-bolus contrast injection and combined vascular-excretory phase scanning are adequate for studying potential renal donors and result in a marked decrease in multiphase scanning and, thus, in radiation dose.

Absorbed radiation dose in radiosensitive organs during coronary CT angiography using 320-MDCT: effect of maximum tube voltage and heart rate variations.

OBJECTIVE: The purpose of this article is to estimate the absorbed radiation dose in radiosensitive organs during coronary MDCT angiography using 320-MDCT and to determine the effects of tube voltage variation and heart rate (HR) control on absorbed radiation dose. MATERIALS AND METHODS: Semiconductor field effect transistor detectors were used to measure absorbed radiation doses for the thyroid, midbreast, breast, and midlung in an anthropomorphic phantom at 100, 120, and 135 kVp at two different HRs of 60 and 75 beats per minute (bpm) with a scan field of view of 320 mm, 400 mA, 320 × 0.5 mm detectors, and 160 mm collimator width (160 mm range). The paired Student's t test was used for data evaluation. RESULTS: At 60 bpm, absorbed radiation doses for 100, 120, and 135 kVp were 13.41 ± 3.59, 21.7 ± 4.12, and 29.28 ± 5.17 mGy, respectively, for midbreast; 11.76 ± 0.58, 18.86 ± 1.06, and 24.82 ± 1.45 mGy, respectively, for breast; 12.19 ± 2.59, 19.09 ± 3.12, and 26.48 ± 5.0 mGy, respectively, for lung; and 0.37 ± 0.14, 0.69 ± 0.14, and 0.92 ± 0.2 mGy, respectively, for thyroid. Corresponding absorbed radiation doses for 75 bpm were 38.34 ± 2.02, 59.72 ± 3.13, and 77.8 ± 3.67 mGy for midbreast; 26.2 ± 1.74, 44 ± 1.11, and 52.84 ± 4.07 mGy for breast; 38.02 ± 1.58, 58.89 ± 1.68, and 78 ± 2.93 mGy for lung; and 0.79 ± 0.233, 1.04 ± 0.18, and 2.24 ± 0.52 mGy for thyroid. Absorbed radiation dose changes were significant for all organs for both tube voltage reductions as well as for HR control from 75 to 60 bpm at all tube voltage settings (p < 0.05). The absorbed radiation doses for the calcium score protocol were 11.2 ± 1.4 mGy for midbreast, 9.12 ± 0.48 mGy for breast, 10.36 ± 1.3 mGy for lung, and 0.4 ± 0.05 mGy for thyroid. CONCLUSION: CT angiography with 320-MDCT scanners results in absorbed radiation doses in radiosensitive organs that compare favorably to those previously reported. Significant dose reductions can be achieved by tube voltage reductions and HR control.

Escalating computed tomography angiogram (CTA) grade predicts unresectability and margin status for pancreaticobiliary neoplasms.

BACKGROUND AND AIMS: The Raptopoulos computed tomography (CT) grading system of pancreaticobiliary cancers was conceived to predict resectability based on tumour involvement of critical vasculature. The aim of the present study was to investigate the relationship between CT grade, resectability, margin status and survival after pancreatic resection. METHODS: Patients with presumed pancreaticobiliary malignancy and a pancreas protocol computed tomography angiogram (CTA) who underwent attempted curative resection from October 2001 and August 2008 were identified. The relationship between radiographical involvement of critical vasculature, according to a five-point scale, and ultimate resectability, margin status and survival was assessed. RESULTS: Overall, 276 (70.2%) out of 393 patients were resectable. The proportion of patients who were unresectable at laparotomy increased as CT grade escalated; 41/250 (16.4%) CT Grade 0, 16/55 (29.1%) CT Grade 1, 33/55 (60%) CT Grade 2, 27/33 CT Grade 3, P < 0.001. Local invasion or vascular involvement was the reason for unresectability in 14/41, 12/16, 23/33, 16/27 patients with CT Grade 0-3, respectively. A R0 resection was achieved in 84/131 patients with pancreatic adenocarcinoma and varied significantly by CT grade, P= 0.021. Significant predictors of survival were age (P < 0.0001), resectability (P < 0.0001) and diagnosis (P < 0.009). CONCLUSIONS: Escalating Raptopoulos CT grade is correlated with increasing probability of unresectability and R1 resection.

Body tumor CT perfusion protocols: optimization of acquisition scan parameters in a rat tumor model.

PURPOSE: To evaluate the effects of total scanning time (TST), interscan delay (ISD), inclusion of image at peak vascular enhancement (IPVE), and selection of the input function vessel on the accuracy of tumor blood flow (BF) calculation with computed tomography (CT) in an animal model. MATERIALS AND METHODS: All animal protocols and experiments were approved by the institutional animal care and use committee prior to study initiation. After injection of 0.2 or 0.4 mL of iodinated contrast material, six rats with mammary adenocarcinoma (three tumors each) were scanned in the axial mode for 5 minutes with 1-second ISD (reference scan), 2.5-mm section thickness, 2.5-mm interval, pitch of 1.3, 120 kV, 240 mA, and 0.5-second rotation time. A total of 126 dynamic data sets were created with commercial software by varying TST and ISD, including or excluding the IPVE, and using the aorta or inferior vena cava (IVC) as the input function. Comparative analyses were used to test for significant differences (t test, Wilcoxon signed rank test). Regression analysis was performed to assess the relationship between attenuation of the input function vessel and BF. RESULTS: No significant difference was observed (P > .05) when TST was as short as 30 seconds (range, 20-23 mL/100 g). In sequences performed with an ISD longer than 8 seconds, BF was significantly elevated (P < .01). Inclusion of the IPVE eliminated this difference (P > .10). Use of the IVC as the input function resulted in significantly higher BF (P < .02), with a correlation between peak attenuation and BF (R(2) = 0.43). CONCLUSION: To reduce radiation dose in tumor perfusion with CT, TST can be reduced without causing significant changes in BF calculation in an animal model. Scanning the aortic reference with peak contrast enhancement reduces variability sufficiently to allow for longer ISDs.

CT and MRI in diseases of the aorta.

OBJECTIVE: This review focuses on the role of CT and MRI in the diagnosis, follow-up, and surgical planning of aortic aneurysms and acute aortic syndromes, including aortic dissection, intramural hematoma, and penetrating aortic ulcer. It also provides a systematic approach to the definition, causes, natural history, and imaging principles of these diseases. CONCLUSION: An understanding of the pathophysiology, natural history, and imaging features is the key to successful diagnosis and appropriate management of patients with these aortic diseases.

Value of customized scan timing determined by tracking liver enhancement in oncology patients.

PURPOSE: To assess the value of liver parenchyma enhancement tracking for liver multidetector computed tomography (CT) in patients with potential hypoattenuating liver metastases. MATERIALS AND METHODS: Institutional review board approved this Health Insurance Portability and Accountability Act-compliant study. We reviewed the chest-abdomen-pelvis CTs of 120 consecutive patients scanned on 16-/64-row multidetector CT after receiving 52 g I in 50 seconds. Liver scanning started 65 seconds after injection-start in 59 patients, whereas in 61 patients, scanning started automatically when liver enhancement reached 50 Hounsfield units on low-dose continuous attenuation tracking. Enhancement of liver parenchyma, aorta, portal, and hepatic veins was measured. Two readers graded conspicuity and recorded attenuation of hypoattenuating lesions. RESULTS: We identified 663 metastases in 74 patients. Scan-delay range in the triggered group was 53 to 83 seconds. Compared with the fixed-delay group, in the triggered group, mean number of metastases per patient with metastases was larger, liver attenuation and enhancement were higher, and median metastasis conspicuity grade was higher (all P < 0.05). CONCLUSIONS: Automatic scan triggering based on liver parenchyma enhancement tracking produces consistently higher liver parenchymal enhancement and increased metastasis conspicuity than fixed delay.

Dose reduction in computed tomographic angiography of pregnant patients with suspected acute pulmonary embolism.

PURPOSE: The aim of this study was to quantify the effect of a reduced-dose pulmonary computed tomographic (CT) angiography protocol on radiation dose and image quality in pregnant patients as compared with a standard protocol. MATERIALS AND METHODS: Twenty-six pregnant women with suspected pulmonary embolism underwent reduced-dose CT angiography (200 mA and 100 kV, from the aortic arch to the diaphragm). The matched control group standard protocol was 400 mA, 120 kilovolt (peak), and the entire thorax. The CT dose index, dose-length product, effective dose, image quality, and signal-to-noise ratio were assessed and compared with the Wilcoxon rank sum test result. RESULTS: The CT dose index, mean dose-length product, and calculated effective dose were lower in the pregnancy group than in the controls: mean (SD), 5.21 (1.54) mGy versus 20.86 (5.59) mGy; 105.65 (39.77) mGy cm versus 575.71 (154.86) mGy cm, and 1.79 (0.676) msv versus 9.787 (2.63) msv, respectively (P < 0.0001). Quality scores of segmental (P = 0.266) and subsegmental (P = 0.207) arteries and arterial attenuation (P = 0.443) were similar. CONCLUSIONS: In pregnant patients with suspected pulmonary embolism, combined reduction of kilovoltage and milliampere-second settings and z-axis coverage results in a substantial reduction of radiation dose while maintaining diagnostic imaging quality.

Measuring noncalcified coronary atherosclerotic plaque using voxel analysis with MDCT angiography: phantom validation.

OBJECTIVE: This purpose of this study was to evaluate the accuracy and reproducibility of a voxel analysis technique for measuring noncalcified plaque in the coronary arteries. MATERIALS AND METHODS: Polyethylene phantoms representing noncalcified plaque were scanned in both MDCT and micro-CT scanners and inter- and intrareader variability of volume calculation was performed. RESULTS: Volume measurements by both MDCT and micro-CT were comparable to the true volume as measured by micrometry (< 3%, p = 0.05). CONCLUSION: There appears to be no significant difference (< 3%) between MDCT and micro-CT measurements.

Measuring noncalcified coronary atherosclerotic plaque using voxel analysis with MDCT angiography: a pilot clinical study.

OBJECTIVE: The purpose of our study was to evaluate a new method using voxel analysis for quantifying noncalcified plaque in coronary arteries using MDCT angiography (MDCTA) compared with luminal stenosis by catheter coronary arteriography. MATERIALS AND METHODS: Forty-one normal and eight abnormal arterial cross sections with noncalcified plaque selected from 40 patients undergoing MDCTA were analyzed for percentage of stenosis and plaque volume using a voxel analysis technique. RESULTS: Using voxel analysis, the normal arterial wall thickness was determined to be 0.8 +/- 0.4 mm. Attenuation values (in Hounsfield units) for normal segments ranged between 30 and 175 H and for abnormal (plaque-containing) segments ranged from -49 to 139 H (p < 0.05). Plaque volume measurements varied from 0.90 to 156 mm(3) with good interobserver correlation (R(2) = 0.9671). Percentage of stenosis correlated with quantitative coronary arteriography measurement (R(2) = 0.55). Voxel analysis underestimated the percentage of stenosis (Pearson's correlation coefficient, 1.2; p = 0.03). CONCLUSION: The study shows that the voxel analysis technique appears to be an accurate and reproducible method to measure arterial wall thickness, noncalcified plaque, and degree of arterial stenosis using density values measured in Hounsfield units. The technique may be useful on further correlative studies.

Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.

OBJECTIVE: The objective of our study was to determine whether perfusion CT can be used to detect early changes in therapeutic response to antiangiogenic therapy in an animal tumor model. MATERIALS AND METHODS: Twenty-five rats implanted with R3230 mammary adenocarcinoma (diameter, 1.2-2.0 cm) randomly received 7.5 or 30 mg/kg of an antiangiogenic agent, sorafenib, by daily gavage for 4 (n = 4), 9 (n = 9), or 14 (n = 5) days. Seven untreated animals served as a control group. Perfusion MDCT was performed at days 0, 4, 9, and 14 with 0.4 mL of ioversol (350 mg/mL) and included four 5-mm slices covering the entire tumor volume. Changes in tumor growth were determined by volumetric analysis of CT data. Serial changes in tumor volume and blood flow were assessed and correlated with pathology findings. RESULTS: All control tumors grew larger (from 2.0 +/- 0.7 cm(3) at day 0 to 5.9 +/- 1.0 cm(3) at day 14), whereas all treated tumors shrank (from 2.5 +/- 1.1 to 2.1 +/- 1.0 cm(3)), with a statistically significant rate of growth or shrinkage in both groups (p < 0.05). Although perfusion in the control tumors changed little from day 0 to day 14 (day 0, 18.1 +/- 9.2 mL/min/100 g; day 4, 15.8 +/- 5.6; day 9, 21.7 +/- 12.2; day 14, 27.7 +/- 34), in the sorafenib group, the mean blood flow was significantly lower at day 4 (5.2 +/- 3.2 mL/min/100 g, 77% decrease), day 9 (6.4 +/- 4.0 mL/min/100 g, 66% decrease), and day 14 (6.3 +/- 5.2 mL/min/100 g, 83% decrease) compared with day 0 (23.8 +/- 11.6 mL/min/100 g) (p < 0.05). Poor correlation was seen between changes in blood flow and tumor volume for days 0-9 (r(2) = 0.34), 4-9 (r(2) = 0.0004), and 9-14 (r(2) = 0.16). However, when comparing day 4 images with days 9 and 14 images, seven of 14 (50%) sorafenib-treated tumors had focal areas of new perfusion that correlated with areas of histopathologic viability despite the fact that these tumors were shrinking in size from day 4 onward (day 4, 2.18 +/- 0.8 cm(3); day 9, 1.98 +/- 0.8 cm(3)). CONCLUSION: Perfusion MDCT can detect focal blood flow changes even when the tumor is shrinking, possibly indicating early reversal of tumor responsiveness to antiangiogenic therapy. Given that changes in tumor volume after antiangiogenic therapy do not necessarily correlate with true treatment response, physiologic imaging of tumor perfusion may be necessary.

Missed lesions at abdominal oncologic CT: lessons learned from quality assurance.

The evaluation of oncology patients represents a substantial volume of the workload in many radiology departments. Interpreting the results of oncologic examinations is often challenging and time-consuming because many abnormalities are identified in the same examination and must be compared with the findings in previous studies. However, errors in the interpretation of oncologic computed tomographic (CT) scans can have significant effects on patient care. These effects may range from withdrawal from a clinical trial or cessation of therapy to repeat CT examination because of a technically inadequate study, CT-guided biopsy of newly identified lesions, or initiation of therapy for previously unrecognized lesions. A root cause analysis of reported errors in the interpretation of abdominal and pelvic CT scans led to the identification of potential pitfalls that may be encountered when interpreting oncologic CT scans and factors that contribute to these errors. Awareness of the spectrum of factors that contribute to misinterpretation of CT scans in oncology patients may improve the performance of the individual radiologist and ultimately translate into improved patient care.

Split-bolus pancreas CTA protocol for local staging of pancreatic cancer and detection and characterization of liver lesions.

PURPOSE: To validate the use of a split-bolus pancreas CTA protocol for local staging of pancreatic cancer and to evaluate its ability to detect and characterize liver lesions. METHODS: Consecutive patients with pancreatic cancer who underwent split-bolus pancreas CTA between 12/2015 and 12/2016 were included in this IRB-approved HIPAA-compliant retrospective study. Objective evaluation of the abdominal vessels, the pancreas, the liver, and lesions, if present, was performed with attenuation measurements and tumor conspicuity and contrast-to-noise ratio (CNR) calculations. An abdominal radiologist with 20 years of experience performed subjective evaluation of image quality and blindly detected and characterized liver lesions. Any inconclusive findings or grading scores were evaluated in consensus with another abdominal radiologist with 7 years of experience. Liver findings were validated using a composite reference standard to assess accuracy. RESULTS: There were 82 pancreatic cancer patients with a total of 91 liver findings. Tumor conspicuity and CNR were 60.8 ± 35.1 HU and 8.0 ± 5.8 for the pancreatic lesions and 58 ± 34.7 HU and 9.7 ± 6.3 for the liver lesions, respectively. The accuracy, sensitivity, and specificity of the split-bolus protocol for the hepatic findings were correspondingly 89/91 (97.8%, 95% CI 92.3-99.4), 58/60 (96.7%, 95% CI 88.6-99.1), and 33/33 (100%, 95% CI 89.6-100). The subjective image quality ratings were optimal in more than 89% of the cases for various structures, with no non-diagnostic ratings. CONCLUSION: Split-bolus pancreas CTA protocol allows for detection and staging of pancreatic cancer, both for the primary tumor and detection and characterization of liver lesions.